Abstract: Provided herein is a potassium-binding polymer prepared by polymerization reaction of a monomer and a crosslinking agent, wherein the monomer is the compound of formula (V), the crosslinking agent is the compound of formula (VI), and/or the compound of formula (VII), wherein the variables are as defined in the specification; to the use thereof for treating or preventing hyperkalemia.

Abstract: This application discloses a power distribution cabinet which includes a cabinet body, a first air duct assembly, and a second air duct assembly. The first air duct assembly is disposed outside the cabinet body, and the first air duct assembly is disposed on the first side wall of the cabinet body. A projection of the first air duct assembly on the first side wall covers the first air vent and the second air vent. A first circulation space is formed between the first air duct assembly and the first side wall. The first circulation space communicates with an internal space of the cabinet body through the first air vent and the second air vent. The second air duct assembly is disposed inside the cabinet body, and the second air duct assembly forms a second circulation space. The second circulation space communicates with the first air vent.

Abstract: The present invention relates to use of the compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof in the manufacture of a medicament or pharmaceutical composition for preventing, treating or lessening POD,

Abstract: A semiconductor etching apparatus includes: a backing ring, a supporting mechanism, an edge ring and a temperature control mechanism. The edge ring is arranged between the backing ring and the supporting mechanism. The temperature control mechanism includes a heating unit arranged below the edge ring. The temperature control mechanism further includes a temperature controller electrically connected with the heating unit.

Abstract: The present invention provides a recombinant protein. The recombinant protein includes an anti-PD-1 antibody and human SIRPA extracellular domain. The N-terminus of the human SIRPA extracellular domain is linked to the C-terminus of the heavy chain of the anti-PD-1 antibody.

Abstract: Provided are a polymer medicament for treating hyperkalemia, and a preparation method thereof. Specifically, a polymer is provided, and the polymer includes repeating units obtained by polymerizing a monomer and a crosslinking agent. A molar ratio of the monomer to the crosslinking reagent ranges from 1:0.02 to 1:0.20. The monomer includes an acidic group and a pKa-reducing group next to the acidic group. The acidic group is selected from the group consisting of sulfonic acid group (—SO3—), sulfuric acid group (—OSO3—), carboxylic group (—CO2—), phosphonic acid group (—OPO32—), phosphate group (—OPO32—), and sulfamic acid group (—NHSO3—). The pKa-reducing group is selected from the group consisting of nitro, cyano, carbonyl, trifluoromethyl, and halogen atoms. The crosslinking agent has three or four reaction sites. The polymer can be used to treat hyperkalemia.

Abstract: The disclosure provides small molecule compounds, polymers, and compositions thereof, as well as methods for preparing such polymers and compositions. Also provided is a method of using the polymers or compositions thereof for binding uric acid or precursor thereof, and/or for treating hyperuricemia, gout, and/or diseases caused by hyperuricemia.

Abstract: The disclosure provides polymers and compositions thereof, as well as methods for preparing such polymers and compositions. Also provided is a method of using the polymers or compositions thereof for binding uric acid or precursor thereof, and/or for treating hyperuricemia, gout, and/or diseases caused by hyperuricemia.

Abstract: A method of treating or preventing a Coronaviridae infection in a subject comprising administrating a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the Coronaviridae comprises at least one selected from 2019-nCov virus, HCov 229E virus, SARS virus, MERS virus,

Abstract: The present invention relates to a method of treating, preventing, or lessening postoperative cognitive dysfunction (POCD) in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof,

Abstract: Provided in the present invention are an anti-OX40 monoclonal antibody or an antigen-binding fragment thereof, and a corresponding isolated polynucleotide, expression vector, recombinant cell, pharmaceutical composition, and application thereof. The present antibody can be used for the treatment of cancer or autoimmune disease.

Abstract: Proposed is an anti-PD-1 monoclonal antibody or an antigen binding fragment thereof, comprising a heavy chain variable region having at least one of the amino acid sequences listed below: (1) the amino acid sequence shown in SEQ ID NO: 1; (2) the amino acid sequence shown in SEQ ID NO: 3; (3) the amino acid sequence shown in SEQ ID NO: 5; and (4) an amino acid sequence having more than one conservative amino acid mutation compared with (1)-(3).

Abstract: The present invention provides a separator for microorganisms in cavitary contents. The separator for microorganisms in cavitary contents includes a raw material vessel, a stage filter, a liquid storage vessel, a closed separated material vessel, a separate loading unit, a deodorizer, pipelines for connecting all the units, etc.

Abstract: Provided is a monoclonal antibody against programmed death-1 (PD-1) or applications thereof, where the monoclonal antibody against PD-1 comprises a neonatal Fc Receptor (FcRn)-binding site having an amino acid sequence of SEQ ID NO: 5.

Abstract: The present invention provides a recombinant protein. The recombinant protein includes an anti-PD-1 antibody and human SIRPA extracellular domain. The N-terminus of the human SIRPA extracellular domain is linked to the C-terminus of the heavy chain of the anti-PD-1 antibody.

Abstract: Provided is a monoclonal antibody against programmed death-1 (PD-1) or applications thereof, where the monoclonal antibody against PD-1 comprises a neonatal Fc Receptor (FcRn)-binding site having an amino acid sequence of SEQ ID NO: 5.

Abstract: Provided a method for increasing binding affinity of an IgG-like antibody to FcRn and prolonging serum half-life thereof The method comprises mutating amino acids at positions 254, 308 and 434 in an FcRn-binding site of a heavy chain constant region of the IgG-like antibody.

Abstract: Disclosed is a pharmaceutical composition, comprising a first component and a second component, wherein the first component is selected from at least one of a farnesoid X receptor agonist and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, an ester and a solvate thereof; and the second component is selected from at least one of a NPC1L1 receptor inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, an ester and a solvate thereof. The composition can be used in preventing and/or treating non-alcoholic fatty liver disease, diabetes or cardiovascular disease.

Abstract: Proposed is an anti-PD-1 monoclonal antibody or an antigen binding fragment thereof, comprising a heavy chain variable region having at least one of the amino acid sequences listed below: (1) the amino acid sequence shown in SEQ ID NO: 1; (2) the amino acid sequence shown in SEQ ID NO: 3; (3) the amino acid sequence shown in SEQ ID NO: 5; and (4) an amino acid sequence having more than one conservative amino acid mutation compared with (1)-(3).

Abstract: The present invention provides a separator for microorganisms in cavitary contents. The separator for microorganisms in cavitary contents includes a raw material vessel, a stage filter, a liquid storage vessel, a closed separated material vessel, a separate loading unit, a deodorizer, pipelines for connecting all the units, etc.